290 related articles for article (PubMed ID: 36646046)
41. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD
Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699
[TBL] [Abstract][Full Text] [Related]
42. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
Black PC; Tangen CM; Singh P; McConkey DJ; Lucia MS; Lowrance WT; Koshkin VS; Stratton KL; Bivalacqua TJ; Kassouf W; Porten SP; Bangs R; Plets M; Thompson IM; Lerner SP
Eur Urol; 2023 Dec; 84(6):536-544. PubMed ID: 37596191
[TBL] [Abstract][Full Text] [Related]
43. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM; O'Donnell MA; Efstathiou JA; Zahurak M; Rosner GL; Smith J; Kates MR; Bivalacqua TJ; Tran PT; Song DY; Baras AS; Matoso A; Choi W; Smith KN; Pardoll DM; Marchionni L; McGuire B; Grace Phelan M; Johnson BA; O'Neal T; McConkey DJ; Rose TL; Bjurlin M; Lim EA; Drake CG; McKiernan JM; Deutsch I; Anderson CB; Lamm DL; Geynisman DM; Plimack ER; Hallman MA; Horwitz EM; Al-Saleem E; Chen DYT; Greenberg RE; Kutikov A; Guo G; Masterson TA; Adra N; Kaimakliotis HZ
Eur Urol; 2023 Jun; 83(6):486-494. PubMed ID: 36717286
[TBL] [Abstract][Full Text] [Related]
44. Single monthly bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer.
Okamura T; Akita H; Ando R; Ikegami Y; Naiki T; Kawai N; Tozawa K; Kohri K
Int J Clin Oncol; 2012 Oct; 17(5):477-81. PubMed ID: 21947596
[TBL] [Abstract][Full Text] [Related]
45. Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.
Kikuchi H; Abe T; Matsumoto R; Osawa T; Maruyama S; Murai S; Shinohara N
Int J Urol; 2022 Mar; 29(3):251-258. PubMed ID: 34894009
[TBL] [Abstract][Full Text] [Related]
46. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
Liu P; Chen S; Gao X; Liang H; Sun D; Shi B; Zhang Q; Guo H
Front Immunol; 2022; 13():1032907. PubMed ID: 36225922
[TBL] [Abstract][Full Text] [Related]
47. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
48. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ.
Takashi M; Wakai K; Hattori T; Furuhashi K; Ono Y; Ohshima S; Ohno Y
Int Urol Nephrol; 2002; 33(1):41-7. PubMed ID: 12090337
[TBL] [Abstract][Full Text] [Related]
49. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
[TBL] [Abstract][Full Text] [Related]
50. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence.
Irie A; Uchida T; Yamashita H; Matsumoto K; Satoh T; Koh H; Shimura S; Iwamura M; Baba S
Int J Urol; 2003 Apr; 10(4):183-9. PubMed ID: 12657096
[TBL] [Abstract][Full Text] [Related]
51. Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison.
Inamoto T; Ubai T; Nishida T; Fujisue Y; Katsuoka Y; Azuma H
Urol Ann; 2013 Jan; 5(1):7-12. PubMed ID: 23662001
[TBL] [Abstract][Full Text] [Related]
52. Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up.
Subiela JD; Rodríguez Faba Ó; Aumatell J; Gonzalez-Padilla DA; Rosales Bordes A; Huguet J; Krajewski W; Algaba F; López Curtis D; Brasero Burgos J; Sánchez González Á; Jiménez Cidre MÁ; Burgos Revilla FJ; Breda A; Palou J
Eur Urol Focus; 2023 Mar; 9(2):325-332. PubMed ID: 36163105
[TBL] [Abstract][Full Text] [Related]
53. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
54. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
55. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
[TBL] [Abstract][Full Text] [Related]
56. A 2-week maintenance regimen of intravesical instillation of bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial.
Kanagawa Urological Research Group (KURG)
Jpn J Clin Oncol; 2012 Sep; 42(9):813-9. PubMed ID: 22761255
[TBL] [Abstract][Full Text] [Related]
57. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.
Witjes JA; Dalbagni G; Karnes RJ; Shariat S; Joniau S; Palou J; Serretta V; Larré S; di Stasi S; Colombo R; Babjuk M; Malmström PU; Malats N; Irani J; Baniel J; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Pisano F; Gontero P; Sylvester R
Urol Oncol; 2016 Nov; 34(11):484.e19-484.e25. PubMed ID: 27639776
[TBL] [Abstract][Full Text] [Related]
58. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up.
Shinka T; Matsumoto M; Ogura H; Hirano A; Ohkawa T
Int J Urol; 1997 Mar; 4(2):139-43. PubMed ID: 9179686
[TBL] [Abstract][Full Text] [Related]
59. Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC).
Farah NB; Ghanem R; Amr M
BMC Urol; 2014 Jan; 14():11. PubMed ID: 24468269
[TBL] [Abstract][Full Text] [Related]
60. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]